Delia Yu

Three-year Efficacy and Safety of Takeda’s Dengue Vaccine Candidate (TAK-003)

Luis Rivera, Shibadas Biswal, Xavier Sáez‐Llorens et al. · Clinical Infectious Diseases · 2021 · 236 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Vianney Tricou, Delia Yu, Humberto Reynales et al. · The Lancet Global Health · 2024 · 225 citations · Full text

Veterinary Medicine, Child Health, Infectious Diseases +17

Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination

Eduardo López‐Medina, Shibadas Biswal, Xavier Sáez‐Llorens et al. · The Journal of Infectious Diseases · 2020 · 106 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17

Safety and immunogenicity of a tetravalent dengue vaccine in children aged 2–17 years: a randomised, placebo-controlled, phase 2 trial

Vianney Tricou, Xavier Sáez‐Llorens, Delia Yu et al. · The Lancet · 2020 · 105 citations

Veterinary Medicine, Immunology, Pediatrics +14

Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study

Xavier Sáez‐Llorens, Vianney Tricou, Delia Yu et al. · The Lancet Infectious Diseases · 2017 · 90 citations

Veterinary Medicine, Immunology, Pediatrics +17